Abstract Parathyroid hormone-related protein (PTHrP) is an important regulator of bone destruction in bone metastatic tumors. Transforming growth factor-beta (TGFb) stimulates PTHrP production in part through the transcription factor Gli2, which is regulated independent of the Hedgehog signaling pathway in osteolytic cancer cells. However, inhibition of TGF-b in vivo does not fully inhibit tumor growth in bone or tumor-induced bone destruction, suggesting other pathways are involved. While Wnt signaling regulates Gli2 in development, the role of Wnt signaling in bone metastasis is unknown. Therefore, we investigated whether Wnt signaling regulates Gli2 expression in tumor cells that induce bone destruction. We report here that Wnt activation by b-catenin/T cell factor 4 (TCF4) over-expression or lithium chloride (LiCl) treatment increased Gli2 and PTHrP expression in osteolytic cancer cells. This was mediated through the TCF and Smad binding sites within the Gli2 promoter as determined by promoter mutation studies, suggesting cross-talk between TGF-b and Wnt signaling. Culture of tumor cells on substrates with bone-like rigidity increased Gli2 and PTHrP production, enhanced autocrine Wnt activity and led to an increase in the TCF/Wnt signaling reporter (TOPFlash), enriched b-catenin nuclear accumulation, and elevated Wnt-related genes by PCR-array. Stromal cells serve as an additional paracrine source of Wnt ligands and enhanced Gli2 and PTHrP mRNA levels in MDA-MB-231 and RWGT2 cells in vitro and promoted tumor-induced bone destruction in vivo in a b-catenin/Wnt3a-dependent mechanism. These data indicate that a combination of matrix rigidity and stromal-secreted factors stimulate Gli2 and PTHrP through Wnt signaling in osteolytic breast cancer cells, and there is significant cross-talk between the Wnt and TGF-b signaling pathways. This suggests that the Wnt signaling pathway may be a potential therapeutic target for inhibiting tumor cell response to the bone microenvironment and at the very least should be considered in clinical regimens targeting TGF-b signaling.
Introduction
Breast and lung cancer cells frequently metastasize to distant organs such as the bone, where they can disrupt normal bone remodeling and induce significant damage to the skeleton [1, 2] . While there have been significant advances in identifying key regulators of tumor-induced bone disease [2] , the mechanisms driving the establishment of tumor cells in bone and the initiation of osteolysis remain unclear.
Upon metastasis to bone, breast and lung tumor cells upregulate their expression of the transcription factor Gli2, which directly promotes the production and secretion of parathyroid hormone-related protein (PTHrP) into the tumor-bone microenvironment [2] . The release of PTHrP and other osteoclast-promoting factors stimulates bone resorption, enabling the release of active transforming growth factor-beta (TGF-b) from the mineralized bone matrix [1, 2] . Previous reports have indicated that TGF-b positively regulates tumor-derived Gli2 and PTHrP expression [3] [4] [5] , and stimulates tumor cell proliferation in bone [1] .
There are many driving forces that influence tumor progression both in the breast and bone, and it is well established that matrix rigidity is a key factor that regulates the invasive potential of breast tumor cells at the primary site of disease [6] [7] [8] . There is increasing evidence that matrix rigidity has a significant impact on tumor cell behavior in the mineralized bone microenvironment, where the stiffness encountered by the breast tumor cells is at least six orders of magnitude higher than those in the breast tissue [2, 9] . The rigidity of the mineralized bone matrix has been shown to enhance mRNA and protein levels of Gli2, PTHrP, and TGF-b ligand (all genes that facilitate cancer growth in bone) in breast and lung cancer cells through mechanotransduction [10] .
Sequencing of the Gli2 promoter identified a Smadbinding element (SBE) and TCF-binding element (TBE) in a regulatory region upstream of the transcription initiation site in keratinocytes [11] establishing a physiological role for both the TGF-b and Wnt signaling pathways as regulators of Gli2. There is ample evidence that Wnt signaling in the breast drives tumor cell growth and invasiveness [12] and clinical data supports this with correlations between genetic alterations in Wnt signaling pathway molecules and patient prognosis [13] ; however, the role of Wnt signaling in promoting cancer cell growth in bone has not been explored.
While autocrine signaling is an important source of Wnt activation in cancer [12, 13] , paracrine signaling also contributes to the regulation of tumor invasiveness and metastasis. Studies characterizing breast tumor-stroma interactions at the primary site have identified Wnt signaling as an essential step in metastatic colonization [14] . Cancer associated fibroblasts (CAFs) have been shown to enhance prostate cancer growth by secreting Wnt ligands [15] and exosomes that promote breast cancer cell invasion and metastasis by activating autocrine Wnt-planar cell polarity signaling [16] .
We, therefore, hypothesized that Wnt signaling, both autocrine and paracrine, in addition to TGF-b signaling, drives Gli2 expression in breast and lung cancer cells that induce bone destruction. The data presented here indicate that downstream Wnt signaling molecules facilitate Gli2 and PTHrP up-regulation, and that this induction occurs (1) following tumor cell culture on substrates with bone-like rigidity, and (2) following exposure to Wnts secreted by human bone marrow stromal cells.
Methods

Cells
The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and a bone metastatic variant generated in our lab was used for all in vitro and in vivo experiments, as previously published [17, 18] . RWGT2 non-small cell lung carcinoma cells were generated in the Mundy lab [19] . The human bone marrow stromal cell line HS5 and weakly metastatic human MCF-7 breast cancer cells were obtained from ATCC. MDA-MB-231, HS5, and MCF-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Cell-gro, Manassas, VA, USA) plus 10 % fetal bovine serum (FBS; Hyclone Laboratories, Logan UT, USA) and 1 % penicillin/streptomycin (P/S; Mediatech, Manassas, VA, USA) and RWGT2 cells were maintained in Minimum Essential Medium alpha (MEMa; Cell-gro, Manassas, VA, USA) plus 10 % FBS and 1 % P/S. All cell lines are routinely tested for changes in cell growth and gene expression. MDA-MB-231 cells were transiently transfected with either TOPFlash, b-catenin/T-cell factor 4 (TCF4), Gli2 WT, mSmad (mS), or mTCF4 (mT) Gli2 promoter [11] , or the 1.1 kb PTHrP promoter [20] by lipofectamine transfection reagent and plus reagent (Invitrogen, Carlsbad, CA, USA) as previously described [4] .
Human bone marrow stromal cells (BMSCs) were collected from a de-identified normal patient bone marrow aspirate kindly provided Dr. Ginger Holt (Vanderbilt University) with ethical consent. Cells were isolated by differential trypsinization, which enriches for the fibroblast population, and cultured for 2-3 weeks in vitro prior to injection in vivo. These cells were characterized as vimentin and a-smooth muscle actin positive (data not shown).
LiCl/sclerostin/2G7 treatments Lithium chloride solution (LiCl, 8 M solution; SigmaAldrich, St. Louis, MO) was added at a final concentration of 20 mM [21, 22] or 40 mM [21] to serum-free DMEM for 24 h. Sclerostin (R&D Systems) was added at a final concentration of 1.5 lg/ml to DMEM or HS5 culture medium as indicated in the figure legends and incubated for 24 h, then conditioned medium was removed and transferred to MDA-MB-231 cells for 24 h incubation prior to RNA harvest. 2G7, a TGF-b neutralizing monoclonal antibody (provided by the Vanderbilt Antibody Core), or control IgG 12CA5 were administered in vitro at 10 lg/ml using the same method as sclerostin treatment.
Substrates
Tissue culture polystyrene and polyacrylamide hydrogels were employed to examine the effects of substrate rigidity on Wnt signaling in 2D in vitro culture. To facilitate cell adhesion and ensure that the surface chemistry was constant for all substrates tested, fibronectin (Fbn) was adsorbed to the surface of the substrates by incubating them in a 4 lg/mL solution of Fbn in PBS at 4°C overnight. Polyacrylamide (PA) hydrogels were synthesized by copolymerizing a 10 % solution of acrylamide and bisacrylamide in water via free-radical polymerization using a redox pair of initiators [tetramethyl ethylene diamine (TEMED) and 10 % ammonium persulphate (APS) in water]. Additionally, acrylic acid N-hydrosuccinimide (NHS) ester was copolymerized to the surface of the gels. The NHS-acrylate layer was then allowed to react with a solution of Fbn in HEPES. To measure the surface concentration of Fbn, coated substrates were incubated in a solution of Fbn antibody (1:1,000) followed by incubation with a secondary HRP-conjugated antibody. The relative amount of adsorbed antibody was then quantified by reaction with 2 0 -azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and subsequent optical density reading at 405 nm. All PUR and PAA substrates were prepared at the same surface concentration of Fbn that yielded an optical density of 0.12 absorbance units cm -2 .
Quantitative real-time RT-PCR (qPCR)
RNA was extracted using RNeasy mini kit (Qiagen), and cDNA was synthesized using Superscript III (Life b-catenin nuclear/cytoplasmic fractionation MDA-MB-231 cells were seeded onto compliant PA gels, TCPS, or TCPS coated in fibronectin (TCPS ? Fbn) at 1.92 9 10 6 cells/well and harvested for cell pellets after 24 h incubation. Pellets were washed 29 with 1XPBS and fractionated into cytoplasmic and nuclear fractions using the NE-PER nuclear and cytoplasmic extraction reagents (Pierce/Thermo Scientific, Rockford, IL, USA), per manufacturer's instructions. Briefly, the cellular membrane was disrupted using lytic buffer to expose the cytoplasmic proteins, which were immediately harvested and stored at -80°C. The remaining nuclear fraction was recovered and lysed to yield the nuclear protein fraction, which was immediately harvested and stored at -80°C.
Western blot
Equal protein concentrations (5 lg) were prepared for loading with Laemmli sample buffer and electrophoresis was performed on SDS-PAGE Mini-Protein II ready gels (Bio-Rad). Proteins were transferred to polyvinylidene fluoride (PVDF) membrane and blocked with 1XTBS containing 1 % Tween 20 (1XTBST) ? 5 % blocking grade dry milk (Bio-Rad; Hercules, CA, USA) for 1 h at room temperature. b-catenin antibody (BD Transduction Laboratories, Bedford, MA, USA) was added at 1:1,000 dilution in blocking buffer overnight at 4°C, and the membrane was probed for 1 h at room temperature in secondary antibody. Following detection, the membrane was stripped using Restore Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL, USA), washed with 1 9 TBST, and re-probed with a 1:5,000 dilution of b-actin antibody (Sigma-Aldrich, St. Louis, MO, USA) as a loading control.
Promoter activation/luciferase assay Gli2 and PTHrP promoter activation was evaluated by the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA), per manufacturer's instructions. MDA-MB-231 cells and RWGT2 cells were transfected as above and sample lysates were read for relative luminescence on a Synergy 2 plate-reader (BioTek, Winooski, VT, USA) and analyzed for subsequent fold change over control vector. All samples were normalized to an internal Renilla luciferase control.
Animals
All animal experiments were conducted with prior approval from Vanderbilt University Institutional Animal Care and Use Committee and were conducted according to NIH guidelines. In the first study, HS5 cells and MDA-MB-231 or RWGT2 cells stably transfected with either shCTNNB1 (b-Catenin) or shSCR (scrambled control) plasmid (SantaCruz) were used for all animal experiments. 250,000 tumor cells or 200,000 tumor cells ? 50,000 stromal cells were injected into the tibia of 4-6 week old athymic nude mice (Harlan). Tumor progression was monitored by weekly X-ray imaging on a XR-60 digital radiography system (Faxitron) at 35kVp for 8 s. Mice were sacrificed at 21 days post tumor cell inoculation and hindlimbs were harvested for ex vivo analysis.
For the second study, 4-6 week old female nude mice were inoculated with 250,000 MDA-MB-231 cells as previously published to induce osteolytic bone destruction in vivo [24] or 200,000 MDA-MB-231 cells ? 50,000 human BMSCs via intratibial injection (MDA-MB-231 n = 9 mice, MDA-MB-231 ? BMSC n = 7 mice). Mice were radiographically imaged once/week for 4 weeks posttumor cell inoculation (Faxitron LX-60) at 35kVp for 8 s and a consistent region of interest within the proximal tibia was analysed for bone destruction using Metamorph (Molecular Devices, Incs) as previously described [4] .
Histology
Hind limbs were dissected at sacrifice, fixed in 10 % formalin for 48 h, and decalcified in EDTA for 2 weeks as previously described [17, 25] . Bone sections were stained with tartrate resistant acid phosphatase (TRAP) and analyzed using ROI measurements in Osteomeasure as previously described [25] .
WNT ligand ELISA After 24 h incubation, conditioned media was harvested from HS5 cells grown on tissue culture plates and treated with either 1.5 lg/ml sclerostin or PBS. Conditioned media was added to high binding EIA/RIA 96-well ELISA plates (Corning Life Sciences) at a 1:10 dilution and allowed to adhere overnight at 4°C. A serial dilution of WNT1, WNT 3a, and WNT5a protein was also added to generate a standard curve (25-0 ng/ml) for use in quantitative analysis. Plates were washed in PBS ? 0.5 % Tween-20, and nonspecific binding was blocked with 3 % bovine serum albumin (BSA) in PBS ? 0.5 % Tween-20. Primary antibody was added for 1 h at room temperature at the following dilutions: WNT1 1:1000, WNT3a 1:5000, WNT5a, 1:10000. HRP conjugated anti-mouse or anti-rabbit secondary antibodies (Santa Cruz Biotechnology) were added for 1 h at room temperature at a 1:1,000 dilution. OPD reagent was added per manufacture's instruction and absorbance was read at 450 nm on a Synergy2 plate reader. All WNT antibodies and control protein were purchased from Abcam.
shRNA-mediated knockdown of b-catenin and Wnt3a
MDA-MB-231 or RWGT2 cells were stably transfected with shRNA for either human b-Catenin (CTNNB1, shCTNNB1) or control shRNA plasmid (scrambled control, shSCR) and HS5 cells were stably transfected with shRNA for either human WNT3A (shWNT3a) or control shRNA plasmid (scrambled control, shSCR; Santa Cruz). For each transfection, 1 lg shRNA plasmid was incubated with 5 lL shRNA Plasmid Transfection Reagent (Santa Cruz, sc-108061) for 45 min at room temperature. The cells were incubated in 200 lL of the shRNA plasmid/ transfection reagent mixture with 0.8 mL transfection medium (Santa Cruz) for 5 h in a 37°C, 5 % CO 2 incubator. After incubation, DMEM plus 20 % heat inactivated FBS and 2 % penicillin/streptomycin was added to the cells for an additional 24 h. Cells were harvested by trypsin for mRNA analysis to verify knockdown. Cells were maintained in DMEM plus 10 % heat inactivated FBS, 1 % penicillin/streptomycin and 3 lg/mL Puromycin.
Statistical analyses
All statistical analyses were performed using InStat version 3.03 software (GraphPad Software, Inc.), and n = 3 biological replicates for all experiments unless indicated otherwise in the figure legend. Columns represent mean/ group ? standard error of the mean (SEM), and p-values were determined using unpaired Student's t-test or ANOVA as indicated in figure legends, where * p \ 0.05, ** p \ 0.01, *** p \ 0.001, and **** p \ 0.0001.
Results
Activation of Wnt signaling stimulates Gli2 and PTHrP transcription in highly metastatic cancer cells known to induce bone destruction Human RWGT2 lung cancer cells and MDA-MB-231 breast cancer cells, which normally express low levels of bcatenin even when plated on TCPS [26] , and weakly metastatic MCF-7 breast cancer cells were transiently cotransfected with a non-degradable form of b-catenin and its co-factor TCF4 to determine the effect of downstream Wnt signaling molecules on Gli2 and PTHrP mRNA induction. Over-expression of b-catenin/TCF4 significantly increased Gli2 and PTHrP mRNA levels by qPCR in both RWGT2 (Fig. 1a, b) and MDA-MB-231 cells (Fig. 1c, d) , and significantly activated the PTHrP promoter region in RWGT2 (Fig. 1e) and MDA-MB-231 cells (Fig. 1f) . Gli2 promoter activity was also increased in MDA-MB-231 cells (Fig. 1f) and modestly increased (non-significant) in RWGT2 cells (Fig. 1e) . In MCF7 human adenocarcinoma cells, overexpression of b-catenin significantly inhibited PTHrP promoter activation and trended toward an inhibition of the Gli2 promoter (Fig. 1g) , suggesting that the stimulatory effects of downstream Wnt signaling on Gli2 and PTHrP are specific for highly metastatic cells known to induce bone destruction.
LiCl treatment, which has been previously reported to up-regulate the Wnt signaling pathway by inhibiting GSK3-b phosphorylation of b-catenin [22] , significantly stimulated the Gli2 and PTHrP promoter regions in RWGT2 cells (Fig. 2a) . Mid-range treatment with LiCL (20 mM) increased PTHrP promoter activity in MDA-MB-231 cells, but this activation was lost with 40 mM treatment (Fig. 2b) . Wnt activation via LiCl treatment did not significantly affect Gli2 promoter activity in MDA-MB-231 cells (Fig. 2b) or Gli2 or PTHrP promoter activity in MCF-7 cells (Fig. 2c ).
Wnt and TGF-b co-regulation of the Gli2 promoter
There is ample evidence that the TGF-b and Wnt signaling pathways crosstalk, both during development [27] and in cancer cells [28] . To this end, we examined the interdependence of Wnt and TGF-b signaling on Gli2 promoter activity in MDA-MB-231 cells using a construct in which the Smad binding element (SBE) or TCF binding element (TBE) located within the Gli2 promoter has been mutated (mS or mT, respectively) [11] . When the SBE was mutated, forced expression of Smad3 had no effect on Gli2 promoter activation as anticipated (Fig. 3a) . Surprisingly, overexpression of b-catenin no longer modestly stimulated the Gli2 promoter as in Fig. 1f , but rather inhibited Gli2 promoter activity when the SBE was mutated (Fig. 3a) , indicating Wnt signaling induction of Gli2 may be dependent on downstream TGF-b signaling. When the TBE was mutated, forced expression of b-catenin did not alter Gli2 promoter activity as anticipated, and Smad3 was able to activate the Gli2 promoter despite the absence of a functional TBE (Fig. 3b) , indicating that TGF-b signaling activation of the Gli2 promoter does not require the TBE.
Substrate rigidity activates autocrine Wnt signaling in breast cancer cells
Previous studies have shown that Wnt and mechanically transduced signaling cross-talk through Src kinase activity [29, 30] , and that matrices with bone-like rigidity enhance Gli2 and PTHrP expression through alterations in TGF-b signaling [9, 10] . Therefore, rigidity may also influence Wnt signaling upstream of Gli2 and PTHrP, which may be important in the context of breast cancer metastasis to bone. To test this, MDA-MB-231 cells were seeded onto substrates representative of breast tissue [Compliant-PA gel containing Fbn to facilitate cell attachment] or trabecular bone [rigid tissue culture polystyrene (TCPS) ? Fbn or without Fbn to rule it out as a confounding factor], as previously published [10] . MDA-MB-231 cells exhibited a [1.5 fold increase in TOPflash activity, a TCF/Wnt signaling reporter, within 4 h of seeding onto rigid substrates (Fig. 4a) , and a 7-fold increase in TOPFlash activity within 24 h when compared to cells plated on compliant PA gels (Fig. 4b) , regardless of fibronectin. It was noted that baseline TOPflash activity was significantly higher at 4 h post-seeding compared to 24 h post-seeding.
MDA-MB-231 cells seeded onto rigid TCPS for 24 h also exhibited greater Wnt signaling activity in a Wnt Signaling PCR-based microarray (SABiosciences) compared to cells seeded onto compliant PA gels through enhanced expression of numerous Wnt signaling molecules ( Table 1) . Validation of Wnt signaling molecules identified in the array are presented in Table 1 .
Furthermore, MDA-MB-231 cells seeded onto rigid TCPS or TCPS ? Fbn substrates showed abundant bcatenin expression in both cytosolic and nuclear fractions, while cells seeded onto compliant PA gels showed a marked decrease (by approximately 50 %) in b-catenin nuclear accumulation (Fig. 4c) . To determine whether stromal cells secrete detectable levels of Wnt ligands and therefore provide a paracrine source of these proteins, conditioned media from the human bone marrow stromal cell line HS5 was evaluated for the secretion of canonical (Wnt3a, Wnt1) and non-canonical (Wnt5a) Wnt ligands. Wnt3a, Wnt1, and Wnt5a proteins were all detected in naïve fibroblasts, with the secretion of non-canonical Wnt5a notably lower than both Wnt3a and Wnt1 (Fig. 5a) . Treatment with sclerostin, a potent Wnt inhibitor that binds to LRP5/6, significantly reduced Wnt3a secretion by fibroblasts, but did not significantly alter Wnt1 or Wnt5a protein levels (Fig. 5a ), suggesting Wnt ligands may be differentially regulated at the receptor level. Treatment of MDA-MB-231 cells with the Wnt inhibitor sclerostin reduced basal Gli2 mRNA levels (Fig. 5b ) when cells were cultured in unconditioned media. Treatment of MDA-MB-231 cells with 100 % HS5-conditioned media (CM), a human bone marrow stromal cell line, significantly increased Gli2 mRNA levels, and this effect was ablated by the addition of sclerostin (Fig. 5b) , indicating the effects of HS5-conditioned media on Gli2 stimulation are mediated entirely via Wnt signaling. Treatment with a TGF-b neutralizing monoclonal antibody 2G7 was not sufficient to reduce endogenous Gli2 mRNA levels, but abolished the stimulatory effect of HS5 CM, as did combined treatment of sclerostin ? 2G7 (Fig. 5b) . Similarly, sclerostin treatment significantly inhibited PTHrP mRNA levels in MDA-MB-231 cells when cells were cultured in un-conditioned media (Fig. 5c ). HS5-conditioned media increased PTHrP mRNA levels, and this effect was blocked by the addition of sclerostin. Treatment with 2G7 alone was not enough to significantly block HS5 CM-mediated increases in PTHrP mRNA levels, but combination of sclerostin ? 2G7 significantly reduced PTHrP mRNA levels (Fig. 5c) . Sclerostin treatment did not significantly reduce endogenous b-catenin levels in MDA-MB-231 cells (Fig. 5d) , likely due to the already low mRNA levels in these cells. HS5 CM dramatically increased b-catenin mRNA levels, and this was blocked by the addition of sclerostin. 2G7 and 2G7 ? sclerostin also blocked HS5 CM induction of b-catenin mRNA levels (Fig. 5d) .
In order to determine whether b-catenin in tumor cells is required for HS5 CM to increase Gli2 mRNA levels, MDA-MB-231 cells expressing stable knockdown of b- 6a) were treated with HS5 CM. In control MDA-MB-231 cells Gli2 mRNA levels were elevated following HS5 treatment, but this stimulatory effect was blocked in the MDA-MB-231-shCTNNB1 cells (Fig. 6b) . Similarly, PTHrP mRNA levels and b-catenin mRNA levels were dramatically elevated following HS5 CM treatment in the MDA-MB-231 control cells only (Fig. 6c, d ), indicating bcatenin is required for HS5 stimulation of Gli2 and PTHrP in tumor cells. A similar effect on Gli2 and PTHrP mRNA levels was observed in RWGT2 cells (data not shown). In order to verify that it is indeed Wnts secreted by HS5 cells that stimulate Gli2 and PTHrP expression in tumor cells, WNT3a, which is abundantly secreted by stromal cells (Fig. 5a ) was stably knocked down in HS5 stromal cells (Fig. 6e) and CM was collected from these cells. When MDA-MB-231 cells were treated with HS5 CM from HS5 control cells, Gli2 (Fig. 6f) , PTHrP (Fig. 6g) and b-catenin (Fig. 6h) mRNA levels significantly increased. The stimulatory effect of the HS5 CM was completely ablated when Wnt3a was knocked down in HS5 cells (Fig. 6f-h ), indicating that Wnt3a in particular is the Gli2 and PTHrPpromoting factor produced by stromal cells. Endogenous PTHrP mRNA levels were also significantly decreased when MDA-MB-231 cells were cultured with HS5 CM with WNT3a knockdown (Fig. 6g) .
Stromal (Fig. 7a) . Similarly, HS5 cells significantly enhanced RWGT2 tumor-induced bone destruction, and this effect was blocked by knockdown of b-catenin in RWGT2 cells (Fig. 7b) . b-catenin knockdown alone did not significantly affect RWGT2-induced bone destruction. Importantly, deletion of WNT3a in HS5 cells significantly reduced the ability of MDA-MB-231 cells to induce bone destruction (Fig. 7c) , indicating that the mechanism by which stromal cells promote tumor-induced bone destruction is dependent on Wnt signaling in tumor cells, and Wnt3a in particular secreted by stromal cells. To determine whether primary human BMSCs could also enhance tumor-induced osteolysis, MDA-MB-231 cells were cultured in conditioned media from primary human BMSCs, which resulted in significantly greater PTHrP mRNA levels in MDA-MB-231 cells in vitro (Fig. 7d) . Co-inoculation of MDA-MB-231 cells with primary human BMSCs significantly enhanced osteolytic lesion area in vivo over the course of 4 weeks (Fig. 7e) .
Discussion
The work presented here demonstrates that Wnt signaling activation stimulates Gli2 and PTHrP production in tumor cells, and that there are multiple sources of Wnt signals in the tumor-bone microenvironment. Matrix rigidity activated autocrine Wnt signaling at the transcription and (Fig. 8) .
Although we have previously demonstrated that Gli2 is necessary for PTHrP production in vivo [4] , constitutive expression of b-catenin did not stimulate the GLI2 promoter in RWGT2 cells, but dramatically increased Gli2 mRNA levels. While it is possible that Wnt signaling may have GLI2-independent effects on PTHrP transcription in these cells, it is also possible that post-transcriptional changes led to this discrepancy. Thus, these differences in transcription may be cell-line specific [4] .
The data presented here indicate that while there is not a synergistic effect of the TGF-b and Wnt signaling pathways in regulating Gli2 and PTHrP transcription, the two signaling pathways cross-talk at the promoter level to regulate these factors. At the promoter level, the Smad binding element (SBE) within the GLI2 promoter is required for full transcriptional activation of GLI2, but the TGF-b inhibitor 2G7 alone did not reduce basal Gli2 mRNA levels in serum-free conditions where autocrine TGF-b signaling levels are low. 2G7 neutralizing activity was confirmed in vitro by blocking recombinant TGF-b induction of Gli2 in MDA-MB-231 cells (data not shown), but its activity was not sufficient to inhibit endogenous Gli2. This is in contrast to deletion of the TGF-b type II receptor (TGFBRII), which is sufficient to reduce Gli2 mRNA levels [4] . These data suggest that basal autocrine TGF-b signaling in these cells is low, but that paracrine TGF-b signaling can activate the TGFBRII and Gli2 transcription. In contrast, the TCF binding element (TCE) was not required for TGF-b stimulation of the GLI2 promoter, but treatment with sclerostin was sufficient to reduce basal Gli2 mRNA levels. These data suggest that the GLI2 promoter may be more sensitive to changes in bcatenin/TCF4 levels downstream of Wnt signaling. We also conclude that TGF-b effects on Gli2 and PTHrP production are likely mediated at least in part through the surrounding stromal cells. Inhibition of TGF-b or Wnt signaling in either stromal cells or tumor cells effectively abolishes HS5 CM-induced increases in Gli2 and PTHrP. Both Wnt and TGF-b signaling may be involved in stromal cell activation of Gli2 and PTHrP in breast cancer cells, and we show here that Wnt3a secreted by stromal cells drives the stromal-cell induced increase in Gli2 and PTHrP mRNA levels. Importantly, we also demonstrate that bcatenin in tumor cells and Wnt3a secreted by stromal cells are required for stromal cells to enhance osteolytic bone destruction. These data suggest that inhibition of Wnt signaling within the bone microenvironment may block these tumorenhancing effects by acting on both tumor and stromal cells.
MDA-MB-231 breast cancer cells express low levels of bcatenin in culture [26] , but also express very high levels of Dkk1, which is a downstream target of Wnt signaling and an indicator of activated Wnt signaling [31] . Tissue culture plastic, which has rigidity comparable to that of trabecular bone, activated the Wnt reporter TOPflash and elevated mRNA levels of Wnt molecules in breast cancer cells. This suggests that breast cancer cells grown on tissue culture plastic may already be in a Wnt ''active'' state, which is consistent with their high basal expression of Dkk1 [31] and may in fact provide a mechanism for this elevated expression. Since hyper-activation of downstream Wnt signaling by either forced expression of b-catenin or LiCl treatment enhanced Gli2 and PTHrP transcription in both RWGT2 and MDA-MB-231 cells, the level of Wnt activity in these cells may still be influenced by micro-environmental cues and have not reached a maximal threshold of Wnt activation. The reduction in nuclear b-catenin when mechano-responsive MDA-MB-231 cells were seeded onto compliant substrates suggests that despite exhibiting high baseline Wnt activity these cells still actively respond to integrin-dependent mechanotransduction [10] and may respond to paracrine signals from the reactive stroma in the bone microenvironment. It is well established that the reactive stroma and cancerassociated fibroblasts (CAFs) promote breast and prostate tumor growth via paracrine signaling at the primary tumor site [32] [33] [34] [35] [36] [37] , and that these cells serve as a source of Wnt and TGF-b ligands to preserve cancer stem cells [38] , promote cancer progression in the primary site [39, 40] , and preserve metastatic colonization [14] . CAFs have also been identified as a source of Wnt ligands adjacent to human prostate tumors that drive prostate tumor growth in a TGFb-Wnt signaling loop [15] . However, these previous studies have assessed Wnt ligands at the mRNA level only. The data presented here indicate for the first time that fibroblastic cells secrete detectable levels of Wnt protein, and that Wnt3a promotes breast cancer-induced bone destruction. There is an extensive body of data showing that fibroblasts are also capable of responding to matrix rigidity [41] [42] [43] , and our preliminary findings suggest that BMSCs seeded onto rigid matrices have a greater capacity to increase Gli2 and PTHrP mRNA levels in tumor cells than BMSCs seeded onto compliant matrices (data not shown), suggesting the rigid bone microenvironment may promote osteolysis at multiple levels. The data presented here indicate that BMSCs, including fibroblasts, fuel osteolytic bone destruction in vivo, potentially by enhancing the production of factors that drive bone destruction such as PTHrP in tumor cells. Our in vivo data suggests that targeting Wnt signaling in stromal cells in combination with conventional therapies may prevent tumor-induced bone destruction.
While there are challenges to targeting Wnt therapeutically, understanding its role in promoting tumor growth in bone in conjunction with signaling pathways like Hedgehog and TGF-b is critical, since inhibitors to these coregulatory pathways are being developed for clinical use [44] [45] [46] [47] . The data presented here suggest that inhibition of Wnt signaling in the tumor-bone microenvironment would be highly efficient if it blocked both autocrine and paracrine signaling, but this would likely have serious side effects on bone formation, since Wnt signaling in chondrocytes [48] and osteoblast precursors is required for normal bone formation [49] . The levels of Wnt ligands secreted by stromal cells within the bone marrow, while sufficient to promote tumor-induced bone destruction, did not result in any marked effect on osteoblast numbers within the bone (data not shown), indicating that any potential pro-osteoblast differentiation effects these stromal-secreted Wnts may have within the bone are negligible to the tumor-induced bone destruction. There was also no change in osteoclast numbers when stromal cells were coinoculated with tumor cells (data not shown), but there is frequently little bone present within the primary spongiosa in these tumor models at endpoint and therefore changes in osteoclast number can be difficult to detect following intratibial inoculation. Surprisingly b-catenin is not required for normal lymphopoiesis and hematopoiesis [50] , which b Fig. 7 Stromal cell promotion of tumor-induced osteolysis is dependent on Wnt signaling. suggests that if the therapeutic challenges to disrupting bone formation could be bypassed there may be minimal off target effects in the bone marrow niche; however, the data presented here showing that Smads were able to stimulate Gli2 transcription in the absence of a functional TCF binding site suggest that both Wnt and TGF-b signaling pathways must be blocked to abrogate Gli2 transcription under the control of autocrine mechanisms. In contrast, Wnt blockade using sclerostin completely blocked BMSC-induced Gli2 transcription, suggesting TGF-b signaling is not required for paracrine induction of Gli2 and PTHrP. It is unclear whether both TGF-b and Wnt inhibition may therefore be required to completely eliminate downstream induction of Gli2 and resulting bone destruction in vivo, but previous work indicates that TGF-b inhibition in vivo partially blocks tumor-induced bone destruction [51] , which may be in part due to inhibition of Wnt effects on Gli2 transcription.
In conclusion, the data presented here show that the rigidity of the bone matrix encountered by tumor cells and the surrounding reactive BMSCs promote the induction of PTHrP and its upstream regulator Gli2 and increase tumorinduced osteolysis, and that these processes are in part driven by the Wnt signaling pathway. As the Wnt and TGF-b signaling pathways continue to be developed for clinical use in a variety of cancers, the involvement of these two pathways in the initiation and propagation of bone destruction merits additional monitoring for bone metastases in patients receiving these therapeutic interventions.
